Go to navigation Go to content
Phone: (404) 474-0804
Jason R. Schultz P.C

J&J, Novartis Recall Fentanyl Pain Patches Over Possible Leak


Posted on Feb 13, 2008

Johnson & Johnson and Novartis AG's Sandoz unit recalled some patches containing the painkiller fentanyl, saying manufacturing defects may cause leaks that can lead to fatal overdoses.

The Duragesic patches, made by Johnson & Johnson's Alza Corp., may have a cut along the drug reservoir, exposing users directly to the fentanyl gel inside, the New Brunswick, New Jersey-based company said in a statement. It's the fifth recall of some version of the patches since 1994.

``Perhaps the time has come for the FDA to order Johnson & Johnson to pull all versions of this product off the shelves,' said Alex MacDonald, a lawyer who represents the families of former patch users. Juries have found defective patches caused the deaths of two users since lawsuits over the products began going to trial in 2006.

Today's recall covers patches in the U.S. and Canada that release 25 micrograms of fentanyl in an hour, Johnson & Johnson said. The expiration dates are on or before December 2009. Duragesic patches generated $1.16 billion in global sales last year, making them Johnson & Johnson's eighth-biggest selling product, spokesman Greg Panico said.

Sandoz distributes the patches. Mylan Inc., based in Canonsburg, Pennsylvania, began selling a lower-cost copy of the Duragesic patch in 2005, and was joined by other companies including Watson Pharmaceuticals Inc.

Safety Warning

The U.S. Food and Drug Administration issued a safety warning in December over the patches, saying improper use can cause breathing difficulties and death. That followed a July 2005 alert put out by the FDA after 120 patients taking the drug died. Johnson & Johnson said in November that it faced 72 lawsuits over the patches.

``The FDA continues to engage with the company in its voluntary recall and is investigating the situation,' FDA spokeswoman Susan Cruzan said in an e-mail.

Johnson & Johnson rose $1.09, or 1.8 percent, to $62.97 in New York Stock Exchange composite trading today. The shares have fallen 5.6 percent this year.

The recall ``is small enough that I doubt this will impact the bottom line,' said Jon Fisher, a portfolio manager at Fifth Third Asset Management in Minneapolis. The fund held 3.1 million shares of Johnson & Johnson as of September, according to data compiled by Bloomberg.

Fentanyl is mostly used to treat cancer pain, according to the FDA, and doctors say it's a stronger painkiller than morphine. Duragesic patches contain fentanyl in a pouch between two membranes. In January, Johnson & Johnson received returned patches that had cut edges, prompting the company to notify the FDA, Panico said.

Read More About J&J, Novartis Recall Fentanyl Pain Patches Over Possible Leak...

back to top


Live Chat